|
 |
VancocinThis page contains recent news articles, when available, and an overview of Vancocin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.On approval, ceftobiprole will have to compete with several established drugs, which include ViroPharma's (Nasdaq: VPHM) Vancocin, Theravance's (Nasdaq: ... Benzinga Zacks Analyst Blog Highlights: Johnson & Johnson, ViroPharma, Theravance ... - Jan 4, 2010 On approval, ceftobiprole will have to compete with several established drugs, which include ViroPharma's (Nasdaq: VPHM) Vancocin, Theravance's (Nasdaq: ... FOXBusiness Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 ... - Nov 12, 2009 In addition, patients treated with fidaxomicin in the first Phase 3 trial experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a ... CNNMoney.com (press release) ViroPharma Incorporated Q3 2009 Earnings Call Transcript - Oct 28, 2009 Certain statements regarding future demand for Cinryze and Vancocin, the timing of any FDA actions related to the potential approval of generic versions of ... Seeking Alpha (blog) ViroPharma Incorporated Reports Third Quarter 2009 Financial Results - Oct 28, 2009 The decrease in adjusted net income for both periods is primarily due to lower Vancocin net sales, lower interest income and higher income tax expense due ... Reuters ViroPharma Incorporated - SWOT Analysis - Aarkstore Enterprise - Oct 26, 2009 The company currently markets Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the US. ViroPharma is headquartered in ... PRMinds (press release) Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile ... - Oct 31, 2009 Subjects with confirmed CDI received either 200 mg fidaxomicin dosed orally twice daily or 125 mg Vancocin dosed orally four times daily. ... Reuters OPTR: Completes Enrollment for Phase 3 Trial of Fidaxomicin for CDI - Nov 12, 2009 In addition, patients treated with fidaxomicin in the first Phase 3 trial experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a ... Trading Markets (press release) UPDATE 1-ViroPharma Q3 lags Street, narrows Cinryze sales view - Oct 28, 2009 ViroPharma's quarterly results slipped below analyst estimates, hurt by lower sales of its antibiotic Vancocin and higher income tax expense, but raised the ... 路透中国 ViroPharma to Present at Three November Healthcare Conferences - Oct 29, 2009 ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium ... Reuters IDSA: Rare MRSA Strain Deadlier than Others - Nov 3, 2009 While USA600 was susceptible to vancomycin (Vancocin) by current standards, it was significantly more tolerant of the antibiotic (at P=0.03) than the other ... MedPage Today Analyst - Zacks Analyst Blog Highlights: Theravance, ViroPharma, Pfizer ... - Oct 27, 2009 Vibativ will have to jostle for space against products like ViroPharma's (Nasdaq: VPHM) Vancocin, Pfizer's (NYSE: PFE) Zyvox and Tygacil. ... Ad-Hoc-News (Pressemitteilung) Vancocin makers shares lose 33% - An FDA change for generic drugs … - Mar 18, 2006 An FDA change for generic drugs may force a key ViroPharma drug to compete sooner than thought. Shares of ViroPharma Inc. plunged 33 percent yesterday on ... $2.95 - Philadelphia Inquirer - NewsBank … company revenue - Record sales of Vancocin put ViroPharma's... - Aug 3, 2006 Record sales of Vancocin put ViroPharma's overall sales up 52 percent as profit more than tripled. ViroPharma Inc.'s revenue rose more than 50 percent in ... $2.95 - Philadelphia Inquirer - NewsBank Shares Rise on Positive Data - Nov 11, 2008 Vancocin was dosed four times daily, also for 10 days. A clinical cure was defined as patients requiring no further therapy for C. diff two days after ... TheStreet.com - TheStreet.com (subscription) ViroPharma Has 65% Upside For Vancocin Pricing - Sep 15, 2005 Piper Jaffray raised the price target on ViroPharma (nasdaq: VPHM - news - people ) to $24 from $18 and said potential price increases for the Vancocin ... Forbes ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 … - Oct 30, 2007 Net sales of Vancocin(R) were $50.9 million for the third quarter of 2007 and ... The continued, robust performance of Vancocin helped grow our working ... Free with registration - PR Newswire - AccessMyLibrary.com Test Drug Does Well Against Hospital Infection - Nov 10, 2008 More serious cases are treated with the approved drug, Vancocin, ... In the clinical trial, both Optimer's drug and Vancocin were nearly 90 percent ... New York Times ViroPharma Shares 'Absolute Floor' Seen At $9 to $10 - Mar 20, 2006 ..."We believe that the generic risk to Vancocin will continue to remain an ... ViroPharma acquired the US rights to Vancocin from Eli Lilly (nyse: LLY - news ... Forbes Health Stocks in Motion - Nov 7, 2005 The company attributed the improved results to Vancocin, a colitis treatment. Vancocin had third-quarter sales of $35.7 million, with prescriptions up 36% ... TheStreet.com - TheStreet.com (subscription) … ViroPharma: Reduced orders for its antibiotic Vancocin helped sink... - May 5, 2006 Earnings drop for ViroPharma: Reduced orders for its antibiotic Vancocin helped sink profit 52.8%. The Exton firm's stocks also fell. ... find Philadelphia ... Pay-Per-View - Philadelphia Inquirer - HighBeam Research Crucial Antibiotic Rescues Biotech Maker's Finances - Nov 9, 2005 ViroPharma, a formerly struggling biotechnology company, sells Vancocin, ... With Vancocin sales expected to more than double this year to $120 million, ... New York Times Ahead of the Bell: ViroPharma upgraded - Jul 16, 2008 Vancocin treats gastrointestinal infections, and it is ViroPharma's only marketed product. ... He thinks Vancocin sales may start declining in 2009, ... Boston Globe … company revenue: Record sales of Vancocin put ViroPharma's overall... - Aug 3, 2006 Key drug propels company revenue: Record sales of Vancocin put ViroPharma's overall sales up 52 percent as profit more than tripled. ... find Philadelphia ... Pay-Per-View - Philadelphia Inquirer - HighBeam Research CORRECT: ViroPharma tumbles earnings - MarketWatch - May 4, 2006 Sales of the company's lead product Vancocin were $29.2 million for the first quarter ... Vancocin, which had 2005 sales of $125.9 million, is used to treat ... MarketWatch ViroPharma sees 2008 net product sales of $210-$235 mln - Jan 9, 2008 The company confirmed the 2007 sales expectation of Vancocin to be within its previously issued range of $202 million to $208 million. ... Reuters Iroko buys rights to Eli Lilly Canada antibiotic - Oct 10, 2007 Vancocin is a potent antibiotic indicated to treat two significant bacterial infections of the lower digestive tract. "This acquisition further augments ... Bizjournals.com ViroPharma Announces Additional Investment for Vancocin Supply - Nov 3, 2005 EXTON, Pa., Nov. 3, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the amendment of its manufacturing agreement with Eli Lilly ... primezone.com … Scientific Arguments In Supplement To Vancocin Petition For Stay... - Jul 4, 2006 Because Vancocin treats two potentially life-threatening diseases, ... ViroPharma commercializes Vancocin(R), approved for oral administration for treatment ... Medical News Today - Medical News Today (press release) ViroPharma Profits Edge Higher - Feb 27, 2008 The company's sales -- derived entirely from its Vancocin antibiotic -- rose to $47.7 million from $38.5 million in the year-ago quarter. ... TheStreet.com - TheStreet.com (subscription) … ViroPharma - Reduced orders for its antibiotic Vancocin helped... - May 5, 2006 Reduced orders for its antibiotic Vancocin helped sink profit 52.8%. ... Sales of Vancocin rose 38.8 percent to $29.2 million, and prescription demand grew ... $2.95 - Philadelphia Inquirer - NewsBank ViroPharma Provides Financial Outlook for 2007. - Jan 8, 2007 ..."I can confirm that our 2006 net Vancocin(R) sales will be within our ... Importantly, cash flows from Vancocin sales again more than fully funded our ... Free with registration - PR Newswire - AccessMyLibrary.com … Files FOIA Complaint Seeking Administrative Record for Vancocin(R) - Dec 18, 2008 In a related action, ViroPharma submitted a FOIA request to FDA for the administrative record relating to FDA's Vancocin bioequivalence guidance of December ... RedOrbit Q4 2006 ViroPharma Earnings Conference Call - Final. - Feb 28, 2007 Certain statements regarding future demand for Vancocin and our estimates of wholesaler ... We grew our net product sales of Vancocin to $167 million. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com AstraZeneca buys out Eli Lilly's Vancocin CP. - Mar 4, 2006 Mar. 4--BANGALORE, India -- AstraZeneca AB has acquired the anti-infective portfolio of Eli Lilly -- Vancocin CP -- for the pharmaceutical markets of India ... Free with registration - Economic Times - AccessMyLibrary.com ViroPharma Provides Update on Vancocin(R) - Dec 15, 2008 EXTON, Pa. , Dec. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today provided the following update regarding Vancocin(R) (vancomycin ... RedOrbit Q2 2007 ViroPharma Earnings Conference Call - Final. - Aug 1, 2007 Certain statements regarding future demand for Vancocin and our estimates ... Next, operationally with Vancocin. We achieved record net product sales of $56 ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com GlobeNewswire, Inc. - News Room - May 3, 2005 ..."Among other things, we completed our integration of Vancocin into our ... Perhaps most importantly, Vancocin had one of its strongest quarters in its ... primezone.com Trouble in the Gut, When Antibiotics Work Too Well - Jan 24, 2006 So far, this bacterium remains susceptible to one or both of two oral antibiotics: Flagyl (metronidazole) and Vancocin (vancomycin), which were used to ... New York Times ViroPharma Provides Update on Vancocin(R) - Jan 8, 2008 EXTON, Pa., Jan. 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today provided the following update on its petition to the US Food and Drug ... RedOrbit Q1 2005 Viropharma Earnings Conference Call - Final. - May 4, 2005 Certain statements regarding future demands for Vancocin, ... We integrated Vancocin into our business and executed a stellar quarter of sales. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com … : A tax benefit and sales of its antibiotic Vancocin powered the... - Mar 1, 2006 Sales of Vancocin were $40.3 million for the quarter ended Dec. ... ViroPharma bought Vancocin from Eli Lilly & Co. in November 2004 for an up-front cash ... Pay-Per-View - Philadelphia Inquirer - HighBeam Research ViroPharma completes Lev Pharmaceuticals buy - Oct 22, 2008 The Exton, Pa.-based biopharmaceutical company's lone product in the market prior to the deal was Vancocin, an antibiotic used to treat bacterial infections. Bizjournals.com … Pharmaceuticals LLC acquires Eli Lilly Canada Inc-Vancocin from Eli... - Oct 10, 2007 CANADA - Iroko Pharmaceuticals LLC acquired the Vancocin product line of Eli Lilly Canada Inc, a manufacturer of prescription, over the counter and ... Pay-Per-View - deals - Alacra Store Article: AstraZeneca buys out Eli Lilly's Vancocin CP. - Economic... - Mar 4, 2006 AstraZeneca buys out Eli Lilly's Vancocin CP. ... find Economic Times (New Delhi, India) articles. Byline: PP Thimmaya Mar. Pay-Per-View - Economic Times - HighBeam Research … ; Drug manufacturer expands agreement with Eli Lilly for Vancocin - Dec 13, 2005 Vancocin is indicated for the treatment of antibiotic-associated pseudomembranous ... Lilly has agreed to continue to manufacture Vancocin through at least ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Feuerstein's Biotech-Stock Mailbag - Aug 11, 2007 Second-quarter earnings easily topped Wall Street estimates and the company raised 2007 sales guidance for Vancocin, its treatment for gastrointestinal ... TheStreet.com - TheStreet.com (subscription) … for debate over generics rule changes.(Cheaper Vancocin Already In... - Jul 31, 2006 This could be painful for ViroPharma, whose Vancocin--an oral capsule form of ... Lilly hadn't been promoting Vancocin, and a longer-established oral ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com … Seeking Administrative Record for Vancocin(R). - PR Newswire | H - Dec 18, 2008 ViroPharma Files FOIA Complaint Seeking Administrative Record for Vancocin(R). from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research GlobeNewswire, Inc. - News Room - Jun 20, 2005 ..."The commercial success of Vancocin to date has opened many doors to ... ViroPharma commercializes Vancocin(R), approved for oral administration for ... primezone.com ViroPharma buys back notes to trim debt - May 11, 2005 Vincent Milano, the company chief financial officer, said "strong sales" of its antibiotic Vancocin Pulvules helped ViroPharma reduce its debt. ... Philadelphia Business Journal … Release: ViroPharma Provides Update on Vancocin(R). - PR Newswire... - Dec 15, 2008 ViroPharma Provides Update on Vancocin(R). from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … announces additional investment for Vancocin supply and US … - Nov 4, 2005 ViroPharma announces additional investment for Vancocin supply and US BioDefense, Inc. updates shareholders on viral inactivation method. from M2 Presswire. Pay-Per-View - M2 Presswire - HighBeam Research ViroPharma files supplement to vancocin petition for stay of action. - May 31, 2006 ViroPharma Inc filed a supplement to its petition for stay of action with the FDA regarding the bio-equivalence requirements for abbreviated new drug ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Zacks Analyst Interview Highlights: Abbott Labs and ViroPharma. - Jan 30, 2007 The stock has been reacting very well lately, and more people are starting to get over their fears about generic Vancocin, which is their lead product. ... $4.95 - Business Wire - ECNext Press Release: ViroPharma Incorporated Reports First Quarter 2008 … - Apr 30, 2008 Net sales of Vancocin(R) were $50.9 million for the first quarter of 2008 as ... The performance of Vancocin was strong, keeping us on track to generate ... Pay-Per-View - PR Newswire - HighBeam Research … Reports Third-Quarter Profit on Strong Vancocin Sales: DHPI, VPHM,... - Nov 8, 2005 ViroPharma Reports Third-Quarter Profit on Strong Vancocin Sales: DHPI, VPHM, NATR, KNBS, ANII. from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Q2 2006 ViroPharma Earnings Conference Call - Part 1. - Aug 2, 2006 Certain statements regarding future demands for Vancocin and their estimates ... Regarding Vancocin operations, we recognize $43.8 million in net sales of ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Approval of Third Party Manufacturing and Supply Chain for Vancocin... - Apr 19, 2006 ..."Vancocin is a product that addresses a life-threatening condition, ... ViroPharma commercializes Vancocin(R), approved for oral administration for ... Free with registration - PR Newswire - AccessMyLibrary.com Event Brief of ViroPharma Conference Call to discuss HCV-796 Phase 1b... - Nov 10, 2005 Roberts got that some people wondered whether this could be, in fact, Vancocin, even if there was no reference at all in that press release to Vancocin. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Veering ViroPharma - Mar 2, 2007 Shares whipsawed down 33% last March over fears of generic competition for its lead antibiotic compound, Vancocin. But the stock later rebounded as the ... fool.com ViroPharma's Sales Estimates Still 'Highly Conservative' - Mar 9, 2006 ..."With at least two groups working on a generic Vancocin including ... "Management at ViroPharma reiterated its 2006 Vancocin sales guidance of $160 million ... Forbes ViroPharma Provides Update On Upcoming FDA Advisory Committee … - Jul 9, 2008 ViroPharma continues to believe that bioequivalence for Vancocin is ... ViroPharma commercializes Vancocin(R), approved for oral administration for ... Medical News Today - Medical News Today (press release) … Reports Third-Quarter Profit on Strong Vancocin Sales: DHPI, VPHM,... - Nov 8, 2005 For Corporate or Company information in regards to SessionsIR, please visit: www.sessionsir.com or contact us at: info@sessionsir.com. ... $4.95 - M2 Presswire - ECNext … Release: ViroPharma Provides Update on Vancocin(R). - PR Newswire... - Jan 8, 2008 ViroPharma Provides Update on Vancocin(R). from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Cowen downgrades ViroPharma to underperform. - Mar 20, 2006 ..."We believe generic versions of Vancocin could be approved in mid-2008, substantially eroding VPHM revenue," he added. Schimmer also said that he did not ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Bucks County Courier Times : EDITORIAL<br> - Dec 3, 2007 According to ViroPharma, the Pennsylvania-based manufacturer of Vancocin, prior to that date the FDA required the use of clinical trials involving human ... $3.50 - Bucks County Courier Times - NewsBank Press Release: ViroPharma Incorporated Reports First Quarter 2006 … - May 4, 2006 Vancocin is the only approved product to treat Clostridium ... complications of the ... Article: ViroPharma Files Supplement to Vancocin Petition for Stay . ... Pay-Per-View - PR Newswire - HighBeam Research … : ViroPharma Comments on Vancocin. - PR Newswire | HighBeam … - Mar 17, 2006 ViroPharma Comments on Vancocin. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … : A tax benefit and sales of its antibiotic Vancocin powered the... - Mar 1, 2006 Sales of Vancocin were $40.3 million for the quarter ended Dec. ... ViroPharma bought Vancocin from Eli Lilly & Co. in November 2004 for an up-front cash ... Free with registration - Philadelphia Inquirer - AccessMyLibrary.com … Release: ViroPharma Files Supplement to Vancocin Petition for Stay... - May 31, 2006 ViroPharma Files Supplement to Vancocin Petition for Stay of Action. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research ViroPharma to join Biotechnology Index - Nov 14, 2005 ...third-quarter sales of $35.8 million -- compared to a $398000 loss in last year's third quarter -- thanks to sales of it s Vancocin antibiotic drug. ... Philadelphia Business Journal ViroPharma Objects to Change In Testing Standards for Vancocin - Apr 5, 2006 The FDA may have changed its bioequivalence testing standards for generic firms seeking to market versions of the antibiotic Vancocin, according the drug's ... Pay-Per-View - Generic Line - Factiva, from Dow Jones Federal Register 2008 - 73 FR 76362 Draft Guidance for Industry on … - Dec 16, 2008 Vancocin (vancomycin HCl) oral capsules, approved by FDA in April 1986, ... Vancocin oral capsules are designated the reference listed drug (RLD) and ... Pay-Per-View - Federal Register 2008 - Loislaw … : ViroPharma Further Comments on Vancocin. - PR Newswire | HighBeam... - Mar 17, 2006 ViroPharma Further Comments on Vancocin. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: ViroPharma Incorporated Reports Fourth Quarter and... - Feb 28, 2007 Net sales of Vancocin(R) were $38.5 million for the fourth quarter of 2006 and ... Importantly, during the fourth quarter of 2006, we achieved net Vancocin ... Pay-Per-View - PR Newswire - HighBeam Research ViroPharma to develop C difficile treatment - Feb 28, 2006 ...of clostridium difficile-associated disease (CDAD) following treatment with Vancocin. The company is currently conducting feasibility studies. ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Viropharma Comments On Upcoming FDA Advisory Committee Meeting - Jun 5, 2008 The risk to patients of a product that is not bioequivalent to Vancocin in this setting is high. "While the notice does not specifically identify Vancocin, ... RedOrbit ViroPharma moves higher; AIG, GM active. - Mar 17, 2006 ViroPharma shares during the day fell more than 30% on concerns that its lead drug Vancocin could be facing generic competition sooner than expected. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com ViroPharma's 'Unparalleled Cash Flow' - Aug 16, 2005 ..."Because Vancocin still represents a very small product in ... The research firm raised the 2006 and 2007 Vancocin sales estimates to $149 million and $167 ... Forbes Event Brief of Q1 2006 ViroPharma Earnings Conference Call - Part 1. - May 4, 2006 VPHM is disappointed with the net sales line for Vancocin for 1Q06. 2. Although underlying prescription demand for Vancocin as measured by IMS was very ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com ViroPharma Incorporated Reports Third Quarter and Nine Months 2006 … - Nov 2, 2006 Net sales of Vancocin were $55.1 million for the third quarter of 2006 and ... "Vancocin continues to serve patients with severe C. difficile as the most ... Free with registration - PR Newswire - AccessMyLibrary.com Zacks Bull and Bear of the Day Highlights: ViroPharma, Equity Office ... - May 8, 2006 The company has one approved product, Vancocin Capsules, for the treatment of antibiotic-associated infection, and two mid-stage candidates for viral ... $4.95 - Business Wire - ECNext ViroPharma to collaborate on C difficile R&D project.(signs Dale... - Mar 6, 2006 The firm says that the research will focus on preventing recurrence of CDAD in patients treated with its antibiotic Vancocin (vancomycin HCl), ... $4.95 - Pharma Marketletter - ECNext Event Brief of Q4 2004 Viropharma Earnings Conference Call - Part 1. - Mar 11, 2005 Net product sales of Vancocin to grow strongly up 15-22% in 2005 over 2004 ... VPHM acquired the rights to Vancocin Pulvules from Eli Lilly & Company, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Career Education Corp seeking buyer for Career Educ Corp-Cert Schools... - Nov 15, 2006 ...…as well as rights to cert ain related Vancocin products from…as well as rights to cert ain related Vancocin products, from…as well as rights to cert ... Pay-Per-View - deals - Alacra Store GlobeNewswire, Inc. - News Room - Jan 19, 2005 Oral Vancocin is a potent antibiotic approved by the US Food and Drug ... The acquisition of Vancocin, which was completed in November of 2004, ... primezone.com Antibiotic Lifts Stock of Exton, Pa., Pharmaceutical Firm - Aug 30, 2005 Now ViroPharma is profitable thanks to an antibiotic called Vancocin that it ... In October, ViroPharma announced it was buying Vancocin for $116 million. ... RedOrbit ViroPharma Could Outperform Market By 30% In Near Term - Sep 20, 2005 SG Cowen continued to recommend purchase of ViroPharma (nasdaq: VPHM - news - people ) and said increased use for the company's lead drug Vancocin, ... Forbes GlobeNewswire, Inc. - News Room - Mar 10, 2005 Vancocin is an important product to us and to our shareholders, not only because it allows us to improve the lives of patients, but also because we expect ... primezone.com Growing Despite the Economy - Dec 24, 2008 The stock came down due to fears we would see generic Vancocin in 2007. ... For generic versions of Vancocin that [do not have substantially the same] ... Moneyshow.com Press Release: ViroPharma Provides Financial Outlook for 2007. - PR … - Jan 8, 2007 ..."I can confirm that our 2006 net Vancocin(R) sales will be within our ... Importantly, cash flows from Vancocin sales again more than fully funded our ... Pay-Per-View - PR Newswire - HighBeam Research 竞争å¨?èƒ?增大ViroPharmaè‚¡ä»·é‡?è·Œ20% - Mar 18, 2006 ...å¸‚åœºæœ‰ä¼ è¨€ç§°ï¼Œè¯¥å…¬å?¸çš„主è¦?产å“?：Vancociné?å?—仿制è?¯ç«žäº‰å¨?èƒ?的时间将早於预期。 ... 2005年，Vancocin的销售é¢?总计1亿2590万美元。该è?¯ä¸»è¦?ç”¨æ–¼æ²»ç–—ä¸ŽæŠ—ç”Ÿç´ æœ‰å…³çš„ä¼ª ... 新浪网 Press Release: ViroPharma Incorporated Reports Third Quarter and Nine... - Oct 30, 2007 Net sales of Vancocin(R) were $50.9 million for the third quarter of 2007 and ... The continued, robust performance of Vancocin helped grow our working ... Pay-Per-View - PR Newswire - HighBeam Research AstraZeneca buys Eli Lilly trademark - Mar 7, 2006 AstraZeneca has announced the acquisition of Vancocin CP (Vancomycin) ... Vancocin CP, widely-considered the treatment of choice for resistant bugs called ... Business Standard Back from the brink - Feb 27, 2008 ViroPharma found Vancocin, an antibiotic that produced sales of $40 million for ... Buying Vancocin in November 2004 would prove to be the best thing that ... $2.95 - Philadelphia Inquirer - NewsBank Sneak Preview: No Borrowed Conviction - Dec 20, 2006 It had recently bought a drug called Vancocin from Eli Lilly (LLY ... Vancocin was the only drug on the market that could treat a certain type of colitis ... TheStreet.com - TheStreet.com (subscription) Merck Pulls Down Drug Stocks - Aug 22, 2005 ..."Because Vancocin still represents a very small product in hospital/insurance formularies and is used to treat severe disease, we do not anticipate ... Forbes Pharma Stocks Flex Some Muscle - Mar 17, 2006 Lazard Capital Markets said it was skeptical the FDA would grant such a waiver for a generic version of Vancocin. The firm said the declines in share prices ... Forbes ViroPharma Likely To Report Positive Phase II Data - Mar 27, 2006 ..."As a reminder, our $13 price target assumes a worst case scenario for Vancocin and $3-$4 per share in value for maribavir." ... Forbes Legal Wins Boost Drug Stocks - May 8, 2006 ..."We remain confident that Vancocin sales can meet our full-year estimate given the 6.8% price increase implemented in February and the increase in demand ... Forbes Black Friday Bargain Stock: ViroPharma - Nov 21, 2007 On the back of its lead compound, an antibiotic named Vancocin, ... ViroPharma started marketing Vancocin after acquiring it from Eli Lilly (NYSE: LLY) in ... fool.com EDITED BRIEF - Apr 30, 2008 Had another good qtr. of Vancocin sales, which positions Co. to meet ... There are new data supporting the use of Vancocin as the drug of choice in patients ... $54.00 - Thomson StreetEvents - Alacra Store ViroPharma Gets No Respect - Oct 30, 2007 Sales of its drug, antibiotic treatment Vancocin, fell $4.2 million to ... In turn, that would mean that Vancocin demand didn't decline year over year. ... fool.com … Approval of Third Party Manufacturing and Supply Chain for Vancocin... - Apr 19, 2006 ..."Vancocin is a product that addresses a life-threatening condition, ... ViroPharma commercializes Vancocin(R), approved for oral administration for ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: ViroPharma Incorporated Reports Third Quarter and Nine... - Nov 2, 2006 Net sales of Vancocin were $55.1 million for the third quarter of 2006 and ... "Vancocin continues to serve patients with severe C. difficile as the most ... Pay-Per-View - PR Newswire - HighBeam Research ViroPharma Responds to Epidemic of Severe Disease Caused By … - Sep 26, 2005 ViroPharma commercializes Vancocin(r), which is indicated for the treatment of antibiotic-associated pseudomembranous colitis caused by C. difficile. ... primezone.com ViroPharma Inc. - Dec 4, 2008 Vancocin and Cinryze are ViroPharma's big commercial drugs. Vancocin is an antibiotic that treats bacterial infections of the lower digestive tract. ... Zacks.com Q2 2005 ViroPharma Earnings Conference Call - Final. - Aug 3, 2005 Certain statements regarding future demand for Vancocin, the likelihood of ... First, as Michel mentioned, our net sales of Vancocin during the second ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com ViroPharma Incorporated Reports First Quarter 2007 Results. - May 2, 2007 Net sales of Vancocin were $49.0 million for the first quarter of 2007, which compares ... Operationally, prescriptions for Vancocin continued to be strong, ... Free with registration - M2 Presswire - AccessMyLibrary.com Press Release: FDA Approves First Generic Versions of Coreg. - M2 … - Sep 5, 2007 FDA's Office of Generic Drugs (OGD) draft guidelines on bioequivalence (BE) for Vancocin (vancomycin hydrochloride) capsules. Vancocin is used to ... ... Pay-Per-View - M2 Presswire - HighBeam Research Highlights of rising and falling US stocks - MarketWatch - Aug 16, 2005 Shares of ViroPharma jumped 29.6% after the company announced plans to raise the price of Vancocin, its colitis treatment, in a filing with the Securities ... MarketWatch |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |